other material
confidence high
sentiment positive
materiality 0.50
Phathom starts patient screening in Phase 3 pHalcon-NERD-302 testing as-needed VOQUEZNA for Non-Erosive GERD
Phathom Pharmaceuticals, Inc.
- Phathom announced initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study of as-needed VOQUEZNA (vonoprazan) 10 mg in adults with Non-Erosive GERD.
- Topline results are expected in the first quarter of 2028; if successful, the study would support a regulatory submission for a VOQUEZNA label expansion.
- The trial is expected to enroll approximately 500 adults with heartburn at least four days per week at roughly 80 U.S. sites.
- After a four-week open-label run-in, patients are randomized 1:1 to VOQUEZNA 10 mg or placebo as-needed for 24 weeks, with the primary endpoint assessed at Week 12.